NEW YORK (GenomeWeb News) – Tokyo-based Koken has acquired the rights to use Alnylam Pharmaceuticals' RNAi-related patents under a non-exclusive, worldwide agreement, Alnylam said today.
Koken will use the patents from Alnylam's Kreutzer Limmer patent family, which covers aspects of the structure and functional properties of synthetic RNAi products, to manufacture and offer siRNA reagents to industry and academic researchers.
Alnylam VP of Business Development Jason Rhodes said in a statement that the company currently has more than 15 license agreements with global research products suppliers, including five in Asia.
"Access to the Kreutzer-Limmer patent estate enables us to augment our current RNAi products, thereby strengthening our position in the life sciences marketplace," Koken President Yuzo Tarumia said.
Financial terms of the agreement were not released.